

Will Stephens
Vice President, Global Access & Partnerships

Janssen Global Services LLC
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
732.524.2404 tel 732.713-1016 tel

Wstephe1@its.jnj.com



Sophia Crabbe-Field
Global Access to Medicines Program
Public Citizen
1600 20th St NW, Washington, DC 20009

Re: Your letter

Dear Sophia,

Thank you for your recent email regarding the Medicines Patent Pool. We appreciate you taking the time to write to us and share your concerns about the important subject of HIV drug access in resource-limited settings.

At Janssen, providing effective and sustainable access to our HIV medicines is an important pillar of our commitment to healthcare around the world. Since 2005, before our first HIV drug was approved, we have been building a comprehensive program to deliver our HIV medicines to patients in the world's poorest countries. At the heart of these efforts is our commitment and responsibility to patients.

We share a common goal with the Medicines Patent Pool, which is to broaden access to HIV medicines in resource-limited countries. We recognize that voluntary licensing, fixed-dose combinations and pediatric formulations are essential components of HIV drug access in resource-limited settings and we are addressing each of these through our HIV drug access program. We have licensed all three of our HIV drugs. Six of these licenses allow for generic versions of our drugs and formulation of our products as fixed-dose combinations (FDCs). In addition, we have announced our intention not to enforce our patents on medically acceptable generic versions of the antiretroviral (ARV) drug *darunavir* used in sub-Saharan Africa (SSA) and Least Developed Countries (LDCs). This policy covers local manufacture, even in the country of origin, provided medically acceptable *darunavir* is provided to SSA and LDCs. We hope this will enable generic manufacturers to meet the need for a sustainable supply of quality, medically acceptable generic *darunavir* for in these countries. Through research collaborations with other pharmaceutical companies, we are developing new FDCs with our HIV medicines to help simplify treatment for patients. And we have child-friendly formulations of all our HIV medicines.

We are confident that our existing access efforts, licensing agreements and policies are providing the best route to extend access to patients in need of our HIV medicines in resource-limited countries. Rest assured we will continue to expand and strengthen our access efforts to ensure we reach the patients who need our HIV medicines in resource-limited countries.



Sincerely,

A handwritten signature in black ink, appearing to read "Will P. Stephens". The signature is written in a cursive style with a long horizontal stroke at the end.

Will P Stephens
VP Global Access and Partnerships Program